Memorial Sloan Kettering Cancer Center

GSK immunotherapy shows promise as alternative to surgery in certain rectal cancers

A small Memorial Sloan Kettering Cancer Center study found that all rectal cancer patients treated with GSK drug Jemperli showed a complete response at six months—there were no detectable signs of the cancer. These early data presented at ASCO suggest that rectal cancer with a particular genetic signature might be treatable with this immunotherapy in lieu of the standard regimen of chemotherapy, radiation, and surgery.

By Frank Vinluan

BioPharma

New study ties pharma payments to prescription practices

Recent efforts to improve transparency haven't made much of a difference, one author noted. But earlier reforms made a dent the "most egregious" practices.

By Joel Berg

Health IT

Reducing Clinical and Staff Burnout with AI Automation

As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.

By Dr. Michael Blackman, Chief Medical Officer at Greenway Health

BioPharma, Legal

Jury awards BMS subsidiary $752M in CAR-T patent infringement suit

A federal jury in California found that Kite Pharma - now part of Gilead Sciences - violated a patent from Memorial Sloan Kettering Cancer Center and licensed to BMS' Juno Therapeutics in developing the CAR-T therapy Yescarta, approved in 2017.

By Alaric DeArment

Pharma, Hospitals

Resignation by Memorial Sloan Kettering’s Baselga should start bigger COI conversation, expert says

Memorial Sloan Kettering Chief Medical Officer Jose Baselga resigned Thursday following publication of a New York Times-ProPublica investigation of his financial relationships with drugmakers.

By Alaric DeArment

Pharma, Hospitals

Report: Top oncologist failed to disclose industry financial relationships

Memorial Sloan Kettering's Dr. Jose Baselga, a top breast cancer doctor, omitted relationships from journal articles, including more than $3 million in payments from Roche, The New York Times and ProPublica reported.

By Alaric DeArment

BioPharma, Startups

Researchers develop ‘armored’ CAR-T with potential against solid tumors

Mouse model study uses PD-1 antibody technology from Eureka Therapeutics, which is also developing T-cell receptor therapies.

By Alaric DeArment

The Future of Hospitals and Pharma Companies Will Depend on Strength of Healthcare Analytics Insights

PurpleLab® stands out from others in this sector by providing its data analytics services to several different groups of users across healthcare and pharma companies.

By Stephanie Baum

Hospitals, Startups

Memorial Sloan Kettering and Cota want to use data to advance cancer treatment

The two New York City-based organizations have partnered on an initiative aimed at precision oncology research and treatment. By leveraging Cota's classification system, Memorial Sloan Kettering will improve patient care and accelerate research efforts.

By Erin Dietsche

Hospitals, Diagnostics

Memorial Sloan Kettering and Philips want to upgrade precision oncology

As part of a new research collaboration, Memorial Sloan Kettering Cancer Center and Philips will be using DNA sequencing technologies to better understand pancreatic cancer.

By Erin Dietsche

Diagnostics

ASCO: MRIs, contrast-enhanced mammography useful for small breast tumors

“There is a real need to detect cancers that are small [less than 1 cm] before they metastasize. That would be the Holy Grail.”

By Julie A. Jacob

Pharma, BioPharma

Drug pricing debates: Can we quantify what a life’s worth?

Industry and academia could be drifting when it comes to evaluating appropriate drug pricing. Here are two views - from venture capitalist Dr. John LaMattina and oncologist Dr. Peter Bach.

By Meghana Keshavan

Exclusive

Heard at HLTH 2024: Insights from Innovative Healthcare Executives

Executives from Imagine360, Verily, BrightInsight, Lantern, and Rhapsody shared their approaches to reducing healthcare costs and facilitating digital transformation.

By MedCity News

Top Story

At ASCO15 meeting: Breakthrough melanoma treatment, Memorial Sloan Kettering oncologist slams cancer drug price tags (Morning Read)

Bristol-Myers Squibb revealed results of Phase 3 study of combined melanoma treatment that could be a cancer treatment breakthrough, but comes with a big price tag and side effects.

By Stephanie Baum

Consumer / Employer